Allergan, Inc.
U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Parsippany
New Jersey
07054
United States
Tel: 1 (862) 261-7000
Website: http://www.allergan.com/
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
YEAR FOUNDED:
1948
LEADERSHIP:
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
1174 articles with Allergan, Inc.
-
The Oklahoma Supreme Court has overturned the landmark $465 million opioid verdict handed down against Johnson & Johnson in 2019.
-
Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting
11/8/2021
Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new pooled post-hoc analyses and patient-reported outcomes (PROs) of VUITYTM (pilocarpine HCl ophthalmic solution) 1.25%, newly approved by the FDA as the first and only eye drop to treat presbyopia; additional analyses on DURYSTA®
-
The decision made VUITY the very first and only eye drop to be approved for the condition.
-
U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision)
10/29/2021
Allergan, an AbbVie company, announced the U.S. Food and Drug Administration approval of VUITY™ 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults.
-
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia
10/26/2021
Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new pooled analyses and post hoc results from the Phase 3 trials of AGN-190584 (pilocarpine HCl ophthalmic solution 1.25%), an investigational novel treatment for presbyopia, at Academy 2021, the annual meeting of the American Academy of Optometry, November 3-6.
-
FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
7/29/2021
Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of BOTOX® to include eight new muscles for the treatment of upper limb spasticity in adults.
-
The company said its new ophthalmic solution met both its primary and key secondary endpoints, with patients reporting near and intermediate improvements in vision.
-
New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
7/25/2021
Allergan, an AbbVie company, announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 ophthalmic solution for the treatment of presbyopia.
-
Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting
7/20/2021
- Data presentations highlight Phase 3 GEMINI 1 trial results on the safety and efficacy of investigational AGN-190584 (pilocarpine 1.25%) as a potential novel treatment for presbyopia, a common and progressive eye condition that reduces the eye's ability to focus on near objects
-
The CMA said some pharmaceutical firms charge the NHS with excessively high prices for hydrocortisone tablets and paid off potential competitors to stay out of the market.
-
Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting
4/27/2021
- New analyses of Phase 3 ARTEMIS studies provide further insights on duration and biodegradation of DURYSTA™ (bimatoprost intracameral implant) - Company will share details of patient-reported outcomes from Phase 3 GEMINI trials for AGN-190584 (pilocarpine 1.25%), a proprietary investigational presbyopia treatment
-
Johnson & Johnson, Endo International, AbbVie’s Allergan unit and Teva Pharmaceutical will head to court this morning in California over claims the companies engaged in deceptive marketing practices that fueled the opioid crisis in America.
-
AbbVie won the NDA on the strength of definitive results in a Phase III ADVANCE trial, where atogepant met all six secondary endpoints at the 30-60 mg dose range, proving statistically significant in heading off migraines in nearly 2500 adult participants who experience them between 4-14 days per...
-
Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia
2/25/2021
Allergan, an AbbVie (NYSE: ABBV) company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia
-
BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition
2/10/2021
Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX® for the treatment of detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.
-
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
1/15/2021
Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA)
-
Toronto Cosmetic Surgery Institute One of the First in Canada to Offer Newest Breast Implant by Allergan
1/5/2021
Patients exploring breast implants commonly search for ways to achieve the full look that still feels soft and natural to the touch, without rippling.
-
Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results for Investigational AGN-190584 for the Treatment of Presbyopia
10/28/2020
Allergan, an AbbVie (NYSE: ABBV) company, today announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint
-
FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity
7/9/2020
Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) that supports expanded use of BOTOX® for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy.
-
Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol
6/26/2020
Allerganannounced that the U.S. Food and Drug Administration has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, a novel, investigational DARPin® therapy for patients with neovascular age-related macular degeneration.